IN2014DN10390A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10390A
IN2014DN10390A IN10390DEN2014A IN2014DN10390A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A IN 10390DEN2014 A IN10390DEN2014 A IN 10390DEN2014A IN 2014DN10390 A IN2014DN10390 A IN 2014DN10390A
Authority
IN
India
Prior art keywords
human patient
nucleotides
treating
lung cancer
small cell
Prior art date
Application number
Other languages
English (en)
Inventor
Chen Duksin
Shoshi Tessler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IN2014DN10390A publication Critical patent/IN2014DN10390A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN10390DEN2014 2012-05-18 2013-05-17 IN2014DN10390A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IN2014DN10390A true IN2014DN10390A (enExample) 2015-08-14

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10390DEN2014 IN2014DN10390A (enExample) 2012-05-18 2013-05-17

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2300257T3 (es) 1999-02-26 2008-06-16 The University Of British Columbia Terapia antisentido contra trpm-2.
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
ES3041855T3 (en) 2010-05-08 2025-11-17 Univ California Radiofrequency sensing method and apparatus for early detection of pressure ulcers
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
SG11201810082VA (en) * 2016-05-13 2018-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
DK3515306T3 (da) 2017-02-03 2025-01-27 Bbi Medical Innovations Llc Måling af modtagelighed for diabetiske fodsår
PT3515296T (pt) 2017-02-03 2023-12-18 Bbi Medical Innovations Llc Medição da viabilidade do tecido
JP6900477B2 (ja) 2017-02-03 2021-07-07 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニーBruin Biometrics, Llc コンパートメント症候群を評価するための装置、およびコンパートメント症候群を検出するためのコンピュータ可読媒体
AU2018368709C1 (en) * 2017-11-16 2025-07-17 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
SI3749181T1 (sl) 2018-02-09 2024-06-28 Bruin Biometrics, LLC, Odkrivanje poškodb na tkivu
CN117596814A (zh) 2018-10-11 2024-02-23 布鲁恩生物有限责任公司 具有一次性元件的装置
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
EP2709673A4 (en) * 2011-05-19 2014-12-17 Teva Pharma METHOD FOR THE TREATMENT OF NON-SMALL CELLULAR CANCER

Also Published As

Publication number Publication date
CN104684564A (zh) 2015-06-03
EP2849761A1 (en) 2015-03-25
KR20150024843A (ko) 2015-03-09
AU2013262589A1 (en) 2015-01-22
WO2013173757A8 (en) 2015-04-30
CA2874092A1 (en) 2013-11-21
BR112014028787A2 (pt) 2017-06-27
US20130310440A1 (en) 2013-11-21
UY34812A (es) 2013-12-31
EA201492148A1 (ru) 2015-04-30
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
TW201402132A (zh) 2014-01-16
AR091090A1 (es) 2014-12-30
IL235459A0 (en) 2014-12-31
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
IN2014DN10390A (enExample)
PH12013502402A1 (en) Method for treating non-small cell lung cancer
NZ603901A (en) Vectors and sequences for the treatment of diseases
NZ715081A (en) Antisense oligomers and conjugates targeting pcsk9
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
MX359548B (es) Agentes de iarn modificados.
PH12015501953A1 (en) Substituted nucleotide analogs
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
AU2009279857A8 (en) Modulation of toll-like receptor 3 expression by antisense oligonucleotides
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
IN2014CN03921A (enExample)
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
WO2012145597A3 (en) Recombinant virus products and methods for inhibition of expression of myotilin
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2015032800A3 (en) Compositions and methods for inducing senescence in cancer cells